ObsEva SA.

NASDAQ:OBSV  
2.74
-0.01 (-0.36%)
Regulatory, Earnings Announcements

Obseva Announces Additional Phase 3 Primrose 1 And 2 Study Results

Published: 12/10/2020 06:07 GMT
ObsEva SA. (OBSV) - Obseva Announces Additional Phase 3 Primrose 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of Linzagolix in the Treatment of Uterine Fibroids.
Primrose 2 76-week Results Show Continued Pain Reduction and Demonstrate Evidence of Bone Mineral Density (bmd) Recovery Following 52 Weeks of Treatment.
Primrose 1 52-week Results Confirm Sustained Efficacy and Continued Safety of Linzagolix (yselty(®)), With a Potential Best-in-class High-dose Option (200 Mg With Add-back Therapy Abt).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.23

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.